Ustekinumab treatment and improvement of physical function and health‐related quality of life in patients with psoriatic arthritis by Rahman, Proton et al.
Arthritis Care & Research
Vol. 68, No. 12, December 2016, pp 1812–1822
DOI 10.1002/acr.23000
VC 2016, The Authors. Arthritis Care & Research published by Wiley
Periodicals, Inc. on behalf of the American College of Rheumatology.
This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited,
the use is non-commercial and no modifications or adaptations are made.
ORIGINAL ARTICLE
Ustekinumab Treatment and Improvement of
Physical Function and Health-Related Quality of
Life in Patients With Psoriatic Arthritis
PROTON RAHMAN,1 LLUIS PUIG,2 ALICE B. GOTTLIEB,3 ARTHUR KAVANAUGH,4
IAIN B. MCINNES,5 CHRISTOPHER RITCHLIN,6 SHU LI,7 YUHUA WANG,7 MICHAEL SONG,7
ALAN MENDELSOHN,7 AND CHENGLONG HAN,8 ON BEHALF OF THE PSUMMIT 1 AND 2 STUDY GROUPS
Objective. To examine the effects of ustekinumab on patient-reported outcomes (PROs) in PSUMMIT 1 and PSUMMIT
2 patients with active psoriatic arthritis (PsA) who were methotrexate (MTX) naive, MTX experienced, or anti–tumor
necrosis factor (TNF) experienced.
Methods. Patients in the phase 3, PSUMMIT 1 (n5 615) and PSUMMIT 2 (n5312) studies randomly (1:1:1) received
placebo, ustekinumab 45-mg, or ustekinumab 90-mg subcutaneous injections at weeks 0, 4, 16, 28, 40, and 52. The
PROs (Health Assessment Questionnaire [HAQ] disability index [DI], Dermatology Life Quality Index [DLQI], 36-Item
Short Form [SF-36] health survey physical (PCS) and mental component summary scores, patient assessments of pain
and disease activity, and impact of disease on productivity) were assessed at weeks 0, 24, and 52. In these post hoc
analyses, outcomes were compared between the ustekinumab and placebo groups for 3 mutually exclusive antecedent-
exposure populations from the combined studies: MTX/anti-TNF naive (placebo, n556; 45 mg, n558; and 90 mg,
n5 66), MTX experienced, biologic agent naive (placebo, n5 192; 45 mg, n5 190; and 90 mg, n5 185), and anti-TNF
experienced with or without MTX (placebo, n5 62; 45 mg, n560; and 90 mg, n5 58).
Results. At week 24, mean improvements from baseline in HAQ DI, DLQI, and SF-36 PCS scores were significantly
greater in both ustekinumab groups versus placebo across antecedent-exposure groups. Greater proportions of
ustekinumab-treated than placebo-treated patients (all P< 0.05) had clinically meaningful improvements in HAQ DI
(‡0.3), DLQI (‡5), and SF-36 (‡5) scores at week 24, irrespective of drug exposure. Improvements in pain, disease
activity, and impact of disease on productivity were similar, and benefits were maintained through week 52.
Conclusion. Significant improvements in PROs with ustekinumab versus placebo were observed in 3 antecedent-
exposure populations of PsA patients, including those with prior MTX and anti-TNF use.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, systemic, inflammatory
disease that can be characterized by peripheral joint pain
and tenderness, skin and nail psoriasis, axial joint involve-
ment, enthesitis, dactylitis, and other manifestations. The
pain and discomfort associated with the joint and skin
symptoms of PsA can limit a patient’s physical function
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and ability to perform daily activities (1,2). The physical
appearance of skin lesions also can cause psychological dis-
tress (3,4) that tends to increase with more severe disease
(1). Several comorbidities, including cardiovascular, are
commonly associated with PsA (5). Therefore, these
patients often have a significantly compromised health-
related quality of life (HRQoL) (1,6,7), including limitations
in physical function and productivity (8).
Ustekinumab, a monoclonal antibody targeting the com-
mon p40 subunit of interleukin (IL)–12 and IL-23, is
approved for treating plaque psoriasis and PsA in adult
patients (9). The safety and efficacy of ustekinumab in
adult patients with active PsA were evaluated in the piv-
otal phase 3, PSUMMIT 1 (10) and PSUMMIT 2 (11) trials.
These studies also demonstrated that ustekinumab treat-
ment can significantly inhibit radiographic progression of
joint damage in patients with active PsA (12). Patients
enrolled into both trials had active disease despite prior
therapies; however, patients who had previously received
anti–tumor necrosis factor (anti-TNF) agents were
excluded from PSUMMIT 1, but eligible for PSUMMIT 2
enrollment.
In both PSUMMIT trials, significant improvements in
patient-reported outcomes (PROs), including in physical
function measured by the Health Assessment Question-
naire (HAQ) disability index (DI), were observed at week
24 in the ustekinumab groups (10,11). Here we report the
results of a post hoc analysis of combined data from
PSUMMIT 1 and PSUMMIT 2, evaluating the effects of
ustekinumab on PROs among patients in 3 mutually
exclusive antecedent-exposure groups: 1) patients who
were biologic agent- and methotrexate (MTX) naive, 2)
patients who were biologic agent naive, but had been
treated with MTX, and 3) patients who had been treated
with an anti-TNF agent with or without MTX.
PATIENTS AND METHODS
Patients and study design. PSUMMIT 1 (NCT01009086)
and PSUMMIT 2 (NCT01077362) were conducted according
to the principles of the Declaration of Helsinki. Governing
ethical bodies at each study site approved the protocols, and
patients provided written informed consent prior to the con-
duct of any study-specific procedures.
Patient eligibility criteria and the study designs of the
phase 3, randomized, placebo-controlled PSUMMIT 1 (10)
and PSUMMIT 2 (11) trials have been described. Briefly,
both trials enrolled adult patients with active PsA for $6
months despite previous treatment with disease-modifying
antirheumatic drugs (DMARDs; $3 months) or nonsteroi-
dal antiinflammatory drugs (NSAIDs; $4 weeks), or ,3
months or 4 weeks, respectively, if DMARDS or NSAIDs
were discontinued due to intolerance. Active PsA was de-
fined as having 5 or more swollen joints (0–66), 5 or more
tender joints (0–68), and a C-reactive protein level$0.3 mg/dl
at screening. Patients also had to have a documented history
of plaque psoriasis or signs of active psoriatic disease.
Patients who had received anti-TNF therapy (i.e., etaner-
cept, adalimumab, infliximab, golimumab, certolizumab
pegol) were excluded from the PSUMMIT 1 trial. However,
patients with prior biologic anti-TNF therapy for$8 (etaner-
cept, adalimumab, golimumab, certolizumab pegol) or $14
(infliximab) continuous weeks (or shorter duration if patient
was intolerant of anti-TNF therapies) were eligible for
enrollment in the PSUMMIT 2 trial. Concomitant use of
other biologic agents was prohibited in both trials.
In both the PSUMMIT 1 (10) and PSUMMIT 2 (11) trials,
enrolled patients were randomized (1:1:1) to receive sub-
cutaneous injections of placebo, ustekinumab 45 mg, or
ustekinumab 90 mg at weeks 0, 4, and every 12 weeks
thereafter through week 24, the primary end point visit. At
week 16, patients with ,5% improvement in tender and
swollen joints entered blinded early escape such that
patients randomized to placebo began receiving ustekinumab
45 mg, those randomized to ustekinumab 45 mg had their
dose increased to 90 mg, and patients randomized to
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ustekinumab 90 mg continued the 90-mg dose. At week 24,
all patients who were randomized to placebo at baseline
were switched to ustekinumab 45 mg. All patients would
continue receiving ustekinumab every 12 weeks through
week 52.
Assessments. In both PSUMMIT 1 and PSUMMIT 2,
PROs were assessed at weeks 0 and 24. Physical function
was assessed using the HAQ DI (13), with a minimal clini-
cally important difference (MCID) defined as an improve-
ment from baseline $0.3 (14). HRQoL was assessed with
the Dermatology Life Quality Index (DLQI) (15) in patients
with $3% body surface area affected by psoriasis, as well
as with the physical and mental component summary
(PCS/MCS) scores of the 36-Item Short-Form (SF-36)
health survey (16). The MCIDs were defined as an
improvement from baseline $5 points for both the DLQI
and SF-36 PCS/MCS scores (17,18). Additionally, a DLQI
score #1 was defined as no impact of disease on HRQoL.
The impact of disease on daily productivity at work,
school, or home was evaluated using a visual analog scale
(VAS; where 05did not affect at all and 105 affected
very much). Patient assessments of pain and disease activ-
ity also were assessed with a VAS ranging from 0 to 10.
Statistical analysis. Data from the PSUMMIT 1 and
PSUMMIT 2 trials were pooled for these post hoc analy-
ses. Descriptive statistics, including counts (percentages),
means (SDs), and mean changes from baseline are
reported. Outcomes were analyzed according to 3 mutu-
ally exclusive antecedent-exposure groups: 1) patients
who were biologic agent- and MTX naive, 2) patients who
were biologic agent naive, but had been treated with MTX,
and 3) patients who had been treated with an anti-TNF
agent with or without MTX. Within each of these groups,
treatment group comparisons were performed between
each ustekinumab dose group and the placebo group using
Cochran-Mantel-Haenszel tests for binary variables and
analyses of variance on the van der Waerden normal
scores for continuous variables. Patients who qualified for
early escape in all 3 treatment groups had their week-16
outcome data carried forward to week 24 for analysis.
To adjust for potential differences in demographic and
baseline disease characteristics between the ustekinumab
and placebo groups, logistic regression models were
employed to derive the odds ratio (OR) for achieving
dichotomous outcomes of DLQI and HAQ DI (see Table 1
for analysis details). Summary statistics were provided for
changes in PROs at week 52.
RESULTS
Baseline characteristics and patient disposition. A
total of 927 patients were randomized and treated in
PSUMMIT 1 (n5 615) and PSUMMIT 2 (n5 312, of which
180 had prior anti-TNF exposure). As previously reported,
baseline demographic and disease characteristics were
generally well-balanced among the treatment groups
within each trial (10,11).
In the pooled analysis, 180 patients were MTX- and bio-
logic agent naive (n5 56/58/66 for placebo/45 mg/90 mg,
respectively), 567 patients had received treatment with
MTX, but not biologic agents (n5192/190/185 for placebo/
45 mg/90 mg, respectively), and 180 patients had received
prior treatment with an anti-TNF agent with or without
MTX (n5 62/60/58 for placebo/45 mg/90 mg, respectively)
(Table 2). Baseline demographic, physical functions, and
HRQoL were generally comparable across the placebo
and ustekinumab dose groups within and across the 3
antecedent-exposure groups, although patients with prior
anti-TNF experience appeared to have more active disease
at study outset than those who did not have prior anti-TNF
exposure (Table 2). Note that the numbers of patients
included in each of the various post hoc analyses are
provided with the reported data.
Improvements in physical function and HRQoL. At
week 24, patients in the ustekinumab groups had
Table 1. Odds ratios (ORs) of ustekinumab (combined) vs. placebo groups for achieving specified HAQ DI and DLQI outcomes
at week 24: results from logistic regression modeling*
Biologic agent and MTX naive
Prior MTX treatment/biologic
agent naive
Prior anti-TNF
treatment6MTX
Outcomes at week 24
(dependent variable) No. OR 95% CI P No. OR 95% CI P No. OR 95% CI P
HAQ DI
HAQ DI score improvement
$0.3 points
179 4.2 1.9–9.0 , 0.001 565 2.2 1.5–3.3 , 0.001 180 3.9 1.6–9.3 0.002
HAQ DI score #0.5 points 179 6.8 2.7–17.4 , 0.001 565 1.7 1.1–2.7 0.018 180 3.2 1.2–8.5 0.02
DLQI
DLQI score improvement
$5 points
179 12.3 4.1–37.1 , 0.001 556 6.4 3.8–11.0 , 0.001 180 8.4 3.0–23.2 , 0.001
DLQI score5 0/1 177 8.2 3.5–19.4 , 0.001 541 3.5 2.3–5.4 , 0.001 164 3.0 1.4–6.2 0.003
* In the logistic regression model for the Health Assessment Questionnaire (HAQ) disability index (DI) improvement $0.3 points or HAQ DI #0.5
points at week 24, the independent variables were age, sex, baseline patient global assessment of disease activity, and baseline HAQ DI. In the
logistic regression model for the Dermatology Life Quality Index (DLQI) improvement $5 points or DLQI5 0 or 1 at week 24, the independent var-
iables were age, sex, baseline patient global assessment of disease activity, and baseline DLQI score. MTX5methotrexate; anti-TNF5 anti–tumor
necrosis factor; 95% CI5 95% confidence interval.
1814 Rahman et al
T
a
b
le
2
.
B
a
se
li
n
e
d
em
o
gr
a
p
h
ic
s,
p
h
y
si
ca
l
fu
n
ct
io
n
,
a
n
d
q
u
a
li
ty
o
f
li
fe
fo
r
p
a
ti
en
ts
w
h
o
h
a
d
n
o
t
re
ce
iv
ed
tr
ea
tm
en
t
w
it
h
M
T
X
o
r
a
b
io
lo
gi
c
a
ge
n
t,
p
a
ti
en
ts
w
h
o
h
a
d
re
ce
iv
ed
p
ri
o
r
M
T
X
tr
ea
tm
en
t,
b
u
t
w
er
e
b
io
lo
gi
c
a
ge
n
t
n
a
iv
e,
a
n
d
p
a
ti
en
ts
w
h
o
h
a
d
re
ce
iv
ed
tr
ea
tm
en
t
w
it
h
a
n
a
n
ti
-T
N
F
a
ge
n
t
w
it
h
o
r
w
it
h
o
u
t
M
T
X
*
B
io
lo
gi
c
a
ge
n
t
a
n
d
M
T
X
n
a
iv
e
P
ri
o
r
M
T
X
tr
ea
tm
en
t/
b
io
lo
gi
c
a
ge
n
t
n
a
iv
e
P
ri
o
r
a
n
ti
-T
N
F
tr
ea
tm
en
t6
M
T
X
P
la
ce
b
o
U
st
.
4
5
m
g
U
st
.
9
0
m
g
U
st
.
co
m
b
in
ed
P
la
ce
b
o
U
st
.
4
5
m
g
U
st
.
9
0
m
g
U
st
.
co
m
b
in
ed
P
la
ce
b
o
U
st
.
4
5
m
g
U
st
.
9
0
m
g
U
st
.
co
m
b
in
ed
P
at
ie
n
ts
ra
n
d
o
m
iz
e
d
,
n
o
.
5
6
5
8
6
6
1
2
4
1
9
2
1
9
0
1
8
5
3
7
5
6
2
6
0
5
8
1
1
8
A
g
e,
y
e
ar
s
4
5
.6
6
1
3
.1
4
8
.4
6
1
2
.3
4
7
.3
6
1
3
.2
4
7
.8
6
1
2
.8
4
8
.0
6
1
1
.7
4
7
.1
6
1
2
.5
4
7
.1
6
4
7
.1
4
7
.1
6
1
1
.3
4
7
.6
6
1
1
.4
4
7
.4
6
1
1
.1
4
7
.7
6
1
2
.6
4
7
.5
6
1
1
.8
M
al
e
,
n
o
.
(%
)
3
4
(6
0
.7
)
3
8
(6
5
.5
)
4
3
(6
5
.2
)
8
1
(6
5
.3
)
9
4
(4
9
.0
)
9
3
(4
8
.9
)
1
0
0
(5
4
.1
)
1
9
3
(5
1
.5
)
3
1
(5
0
.0
)
2
3
(3
8
.3
)
2
2
(3
7
.9
)
4
5
(3
8
.1
)
P
at
ie
n
t
a
ss
e
ss
m
e
n
t
o
f
p
a
in
(0
–
1
0
)
6
.0
6
2
.1
6
.1
6
2
.0
6
.3
6
1
.9
6
.2
6
1
.9
6
.1
6
2
.0
6
.3
6
1
.9
6
.5
6
1
.8
6
.4
6
1
.9
6
.8
6
1
.9
7
.1
6
1
.7
7
.1
6
1
.9
7
.1
6
1
.8
P
at
ie
n
t
g
lo
b
a
l
a
ss
es
sm
e
n
t
o
f
d
is
e
as
e
a
ct
iv
it
y
(0
–
1
0
)
6
.1
6
2
.0
6
.2
6
2
.1
6
.1
6
2
.0
6
.2
6
2
.0
6
.1
6
2
.0
6
.3
6
1
.9
6
.4
6
1
.9
6
.4
6
1
.9
6
.5
6
2
.0
7
.1
6
1
.8
6
.9
6
2
.1
7
.0
6
1
.9
H
A
Q
D
I
sc
o
re
(0
–
3
)
1
.0
9
6
0
.6
9
1
.0
8
6
0
.6
5
1
.0
5
6
0
.6
2
1
.0
6
6
0
.6
3
1
.2
8
6
0
.6
5
1
.2
7
6
0
.6
1
1
.2
7
6
0
.6
2
1
.2
7
6
0
.6
1
1
.2
6
6
0
.7
0
1
.4
1
6
0
.7
1
1
.4
1
6
0
.7
2
1
.4
1
6
0
.7
1
P
at
ie
n
ts
w
it
h
H
A
Q
D
I
sc
o
re
.
0
.5
,
n
o
.
(%
)
4
3
(7
6
.8
)
4
5
(7
7
.6
)
5
1
(7
7
.3
)
9
6
(7
7
.4
)
1
6
2
(8
4
.4
)
1
6
1
(8
4
.7
)
1
5
9
(8
5
.9
)
3
2
0
(8
5
.3
)
5
0
(8
0
.6
)
5
2
(8
6
.7
)
4
8
(8
2
.8
)
1
0
0
(8
4
.7
)
D
L
Q
I
sc
o
re
(0
–
3
0
)
1
2
.2
6
8
.2
1
1
.3
6
7
.3
1
0
.0
6
6
.2
1
0
.6
6
6
.7
1
1
.8
6
7
.5
1
1
.2
6
7
.2
1
0
.8
6
7
.5
1
1
.0
6
7
.3
1
1
.4
6
7
.9
1
2
.3
6
8
.3
1
3
.3
6
8
.4
1
2
.8
6
8
.3
S
F
-3
6
P
C
S
sc
o
re
(0
–
1
0
0
)
3
2
.8
6
8
.9
3
3
.4
6
8
.1
3
3
.8
6
9
.2
3
3
.6
6
8
.6
3
0
.8
6
8
.4
3
0
.3
6
8
.4
3
0
.5
6
7
.4
3
0
.4
6
7
.9
3
0
.1
6
1
0
.5
2
7
.4
6
8
.6
2
7
.2
6
8
.9
2
7
.3
6
8
.7
S
F
-3
6
M
C
S
sc
o
re
(0
–
1
0
0
)
4
4
.1
6
1
1
.0
4
2
.9
6
1
1
.3
4
5
.6
6
1
1
.2
4
4
.3
6
1
1
.3
4
2
.2
6
1
1
.2
4
2
.7
6
1
1
.3
4
2
.6
6
1
1
.6
4
2
.6
6
1
1
.4
4
4
.6
6
1
2
.4
4
3
.8
6
1
3
.0
4
2
.7
6
1
2
.5
4
3
.2
6
1
2
.7
Im
p
ac
t
o
f
d
is
ea
se
o
n
p
ro
d
u
c
ti
v
it
y
(0
–
1
0
)
5
.7
6
2
.7
5
.9
6
3
.3
5
.4
6
2
.9
5
.6
6
3
.1
6
.0
6
2
.6
6
.1
6
2
.7
6
.5
6
2
.6
6
.3
6
2
.6
6
.0
6
2
.9
6
.9
6
2
.6
7
.0
6
2
.3
7
.0
6
2
.4
*
V
a
lu
e
s
a
re
th
e
m
e
a
n
6
S
D
u
n
le
ss
o
th
e
rw
is
e
in
d
ic
a
te
d
.
M
T
X
5
m
e
th
o
tr
e
x
a
te
;
a
n
ti
-T
N
F
5
a
n
ti
–
tu
m
o
r
n
e
c
ro
si
s
fa
c
to
r;
U
st
.5
u
st
e
k
in
u
m
a
b
;
H
A
Q
5
H
e
a
lt
h
A
ss
e
ss
m
e
n
t
Q
u
e
st
io
n
n
a
ir
e
;
D
I
5
d
is
a
b
il
it
y
in
d
e
x
;
D
L
Q
I
5
D
e
rm
a
to
lo
g
y
L
if
e
Q
u
a
li
ty
In
d
e
x
;
S
F
-3
6
5
3
6
-I
te
m
S
h
o
rt
F
o
rm
h
e
a
lt
h
su
rv
e
y
;
P
C
S
5
p
h
y
si
c
a
l
c
o
m
p
o
n
e
n
t
su
m
m
a
ry
;
M
C
S
5
m
e
n
ta
l
c
o
m
p
o
n
e
n
t
su
m
m
a
ry
.
Improving HRQoL With Ustekinumab Treatment in PsA 1815
significantly greater improvements from baseline in HAQ
DI scores when compared with the placebo group for
patients who were MTX- and biologic agent naive (45 mg:
20.33, 90 mg: 20.42 versus placebo: 20.01; P, 0.001),
patients previously treated with MTX but biologic agent
naive (45 mg: 20.29, 90 mg: 20.35 versus placebo: 20.12;
P, 0.001), and for patients previously treated with an anti-
TNF agent with or without MTX (45 mg: 20.18, 90 mg:
20.19 versus placebo: 20.02; P, 0.05) (Figure 1A). In
addition, significantly greater proportions of ustekinumab
than placebo-treated patients had a clinically meaningful
improvement in HAQ DI ($0.3) in each antecedent-
exposure group (Figure 1B). Consistent findings were gen-
erally observed when the proportions of patients with a
HAQ DI score #0.5 at week 24, among those with baseline
HAQ DI.0.5, were compared (Figure 1C).
HRQoL was evaluated with both the DLQI and SF-36 mea-
sures. Mean changes from baseline to week 24 in DLQI were
significantly greater for patients in the ustekinumab groups
than those in the placebo group among MTX- and biologic
agent–naive patients (45 mg: 27.6, 90 mg: 27.7 versus pla-
cebo: 21.3; P,0.001), patients previously treated with
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Figure 1. Mean change from baseline in the Health Assessment Questionnaire (HAQ) dis-
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MTX but biologic naive (45 mg: 26.4, 90 mg: 27.2 versus
placebo: 21.5; P, 0.001), and patients previously treated
with an anti-TNF agent with or without MTX (45 mg: 26.7,
90 mg: 27.6 versus placebo: 20.3; P, 0.001) (Figure 2A).
Results of this analysis showed that greater proportions of
ustekinumab-treated patients in each of the 3 antecedent-
exposure groups had an improvement in DLQI score $5 or
achieved a DLQI score of 0 or 1 compared with placebo (Fig-
ures 2B, 2C).
Improvements in SF-36 PCS scores from baseline to
week 24 were significantly greater in both ustekinumab
dose groups than in the placebo group in each of the 3
antecedent-exposure groups (see Supplementary Figure 1A,
available on the Arthritis Care & Research web site
at http://onlinelibrary.wiley.com/doi/10.1002/acr.23000/
abstract). Likewise, significantly greater proportions of
patients in the ustekinumab groups achieved an improve-
ment from baseline to week 24 $5 points in SF-36 PCS
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score (Supplementary Figure 1B, available at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23000/abstract).
Improvements from baseline in SF-36 MCS scores were
significantly greater in the ustekinumab 45-mg and com-
bined dose groups when compared with placebo among
patients who were MTX- and anti-TNF naive, and were
significantly greater in the ustekinumab 90-mg and com-
bined dose groups when compared with placebo among
the MTX-experienced patients (see Supplementary Figure
2A, available on the Arthritis Care & Research web site
at http://onlinelibrary.wiley.com/doi/10.1002/acr.23000/
abstract). The proportion of patients who had an improve-
ment in SF-36 MCS score$5 points was generally numeri-
cally greater in the ustekinumab groups than in the
placebo group in each antecedent-exposure group (Sup-
plementary Figure 2B, available at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23000/abstract).
Patient perception of pain and disease activity im-
proved at week 24. The median percent improvements
from baseline in pain and patient global assessment of dis-
ease activity were significantly greater in the ustekinumab
groups than in the placebo groups within each of the 3
antecedent-exposure groups (Table 3). Similarly, median
percent improvements in the impact of disease on daily
productivity were significantly greater in the ustekinumab
groups within each antecedent-exposure group (Table 3).
Logistic regression analyses were employed to adjust for
differences in demographic and baseline disease charac-
teristics, including patient global disease activity, DLQI,
or HAQ DI, between the ustekinumab and placebo groups.
After these adjustments, patients in the ustekinumab
groups were more likely to achieve clinically meaningful
improvement in DLQI ($5) or HAQ DI ($0.3) score and
more likely to achieve a normal DLQI (#1) or HAQ DI
(#0.5) score at week 24 than those in the placebo groups
within each antecedent-exposure group (Table 1).
Improvements in all outcomes were numerically lower
in patients with increasing therapeutic experience. How-
ever, although the trials were not designed for this pur-
pose, the overlapping 95% confidence intervals (95% CIs)
surrounding the ORs determined via logistic regression
(Table 1) suggest the differences between antecedent-
exposure groups in efficacy response are not statistically
significant.
The improvements in PROs observed in ustekinumab-
treated patients through week 24 were generally main-
tained through week 52 (Table 4). Additionally, patients
randomized to placebo who crossed over to ustekinumab
45 mg at week 24 had improvements in PROs that were
generally comparable to week-24 improvement among
patients randomized to ustekinumab at baseline (Table 4).
DISCUSSION
Psoriatic diseases affect 2% to 3% of the world’s popula-
tion, and both psoriasis and PsA can carry significant bur-
dens of pain and physical disability, psychological distress,
depression, and impaired productivity. Reflecting the dis-
ability that accompanies concurrent joint disease, patients
with PsA have been shown to have significantly worse
HRQoL than psoriasis patients, both overall (19) and in
terms of physical disability and pain, even in the context of
more aggressive DMARD treatment of PsA (20). In psoriasis
patients, quality of life as assessed by the DLQI has been
found to be more strongly associated with overall costs of
care than the extent of disease as assessed by the Psoriasis
Area and Severity Index score (21). Additional factors that
correlate with cost of psoriasis, most notably due to costs of
time away from work, are the presence of joint involvement
(i.e., concurrent PsA) and receipt of systemic therapy (21).
As previously reported, ustekinumab-treated patients
had significantly greater improvements in physical func-
tion and HRQoL measures from baseline to week 24 when
compared with the placebo groups in both PSUMMIT 1
and PSUMMIT 2 (10,11). Given the heterogeneity of treat-
ment and disease courses that can be observed in PsA
patients, we performed post hoc analyses combining
patient data from the PSUMMIT 1 and PSUMMIT 2 trials
according to 3 mutually exclusive antecedent-exposure
groups: 1) patients who were biologic agent and MTX
naive, 2) patients who were biologic agent naive, but had
been treated with MTX, and 3) patients who had been
treated with an anti-TNF agent with or without MTX.
Significant improvements in physical function (HAQ
DI) and HRQoL (DLQI) from baseline to week 24 with
ustekinumab versus placebo were observed in all 3
antecedent-exposure populations. Notably, greater propor-
tions of ustekinumab-treated patients in each of the 3
antecedent-exposure groups had an improvement in HAQ
DI score $0.3, had an improvement in DLQI score $5, or
achieved a DLQI score of 0 or 1 compared with placebo,
indicating clinically meaningful improvements in physi-
cal function and HRQoL. Similar patterns of improvement
were observed for the SF-36 MCS and PCS scores, impact
of disease on daily productivity, and patient assessments
of pain and global disease activity. Importantly, improve-
ments in function and quality of life accrued through
week 24 appeared to be sustained through week 52. The
SF-36 findings are particularly salient given that PsA
patients experience significant impairment in HRQoL,
with higher levels of bodily pain and more role limitations
due to emotional problems than patients with rheumatoid
arthritis after adjusting for observed differences in vitality
(6). Also of note, our overall findings were consistent with
those from analyses employing logistic regression models,
i.e., after adjustment for baseline and other demographic
characteristics, ustekinumab treatment was consistently
associated with positive treatment outcomes related to
HAQ DI and DLQI, and no significant interactions were
found between treatment and prior treatment histories
(data not shown).While patients in the prior–anti-TNF
group overall had relatively smaller improvements in
HRQoL across treatment groups, the active treatment ver-
sus placebo deltas were generally comparable to those
observed in the MTX-naive group. In addition, the over-
lapping 95% CIs surrounding the ORs determined via
logistic regression analysis for key efficacy outcomes sug-
gest the differences observed among antecedent-exposure
groups are not statistically significant.
A slight difference in baseline disease severity between
ustekinumab groups versus placebo patients in each of the
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3 antecedent-exposure groups was observed. To adjust for
difference in demographic and baseline disease characteris-
tics, including patient global disease activity, DLQI, or
HAQ DI between the ustekinumab and placebo groups,
logistic regression models were employed to derive ORs for
dichotomous outcomes in DLQI and HAQ DI (dependent
variable). Overall, the results were consistent between uni-
variate and regression models, i.e., ORs for achieving clini-
cally meaningful improvements in, and normalized, DLQI
or HAQ DI scores in the ustekinumab group versus the pla-
cebo group were comparable between the prior–anti-TNF
and MTX-naive groups.
A potential limitation of these post hoc analyses is the
difference in sample sizes among the antecedent-exposure
groups, with more than 3 times as many patients (n5 567)
having received treatment with MTX but not biologic
agents than being MTX and biologic agent naive (n5 180)
or having received prior treatment with and anti-TNF
agent with or without MTX (n5 180). A randomized trial
designed to prospectively assess differences among
patients with specific treatment histories may help to fur-
ther validate the findings from this post hoc analysis. As
another limitation, productivity was assessed using a sin-
gle rating scale. Future evaluations should include addi-
tional and more comprehensive measures of productivity.
Results related to mental health should also be interpreted
with caution based on the fact that these post hoc analyses
did not include information related to comorbidities such
as major depression or concomitant antidepressant treat-
ment. Also, the SF-36 is a generic tool for assessing
HRQoL. As such, use of a PsA-specific tool for assessing
HRQoL would provide valuable information and should
be included in future research. Formal testing of interac-
tions should be performed to determine if prior treatment
differentially influences responses on these PRO measures
in these trials. Finally, due to differences in patient popu-
lations and trial designs, our results cannot be directly
compared with those from other studies. In the future, a
meta-analysis and/or trial with a head-to-head comparison
design would be appropriate for drawing such conclu-
sions. In summary, the results of the pooled analysis of
PsA patients by antecedent-exposure groups support the
earlier findings from the primary analyses of the individ-
ual PSUMMIT 1 and PSUMMIT 2 clinical trials that
showed significant improvements in patient HRQoL with
ustekinumab versus placebo. Findings reported herein
indicate that significant improvements in these PROs with
ustekinumab were observed regardless of prior PsA treat-
ment. However, given that delays in effective treatment of
PsA patients can result in more refractory disease, earlier
treatment is more likely to lessen the high prevalence of
the disease burdens of PsA.
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